-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anti-RIPK1 Inhibitor in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anti-RIPK1 Inhibitor in Autoimmune Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Anti-Ripk1 Inhibitor in Autoimmune Disorders Drug Details:The drug candidate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cilostazol CR in Intermittent Claudication
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cilostazol CR in Intermittent Claudication report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cilostazol CR in Intermittent Claudication Drug Details: Cilostazol CR (PMR)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aprepitant in Chemotherapy Effects
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Aprepitant in Chemotherapy Effects Drug Details:Aprepitant is under development for the treatment of dermatological related side...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Devimistat in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Devimistat in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Devimistat in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details:Devimistat (CPI-613)...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastrointestinal stromal tumors (GIST) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. Its treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy. The Gastrointestinal Stromal Tumor pipeline market research report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Small Molecule for Diabetic Foot Ulcers
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Small Molecule for Diabetic Foot Ulcers Drug Details Small molecule is under development for...